Aptevo Therapeutics Inc.

AI Score

XX

Unlock

0.67
-0.02 (-3.12%)
At close: Apr 25, 2025, 3:59 PM
0.66
-1.30%
After-hours: Apr 25, 2025, 05:58 PM EDT
-3.12%
Bid 0.64
Market Cap 2.16M
Revenue (ttm) n/a
Net Income (ttm) -24.13M
EPS (ttm) -87.38
PE Ratio (ttm) -0.01
Forward PE -0.05
Analyst Buy
Ask 0.67
Volume 390,140
Avg. Volume (20D) 2,849,780
Open 0.66
Previous Close 0.69
Day's Range 0.62 - 0.69
52-Week Range 0.60 - 51.06
Beta 5.75

About APVO

Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational ...

Industry Biotechnology
Sector Healthcare
IPO Date Jul 20, 2016
Employees 37
Stock Exchange NASDAQ
Ticker Symbol APVO
Full Company Profile

Analyst Forecast

According to 1 analyst ratings, the average rating for APVO stock is "Buy." The 12-month stock price forecast is $296, which is an increase of 44059.33% from the latest price.

Stock Forecasts
3 weeks ago
+44.2%
Aptevo Therapeutics shares are trading higher. The... Unlock content with Pro Subscription
4 months ago
Aptevo Therapeutics shares are trading lower after the company announced a 1-for-37 reverse stock split.